James E. Bradner - 09 Feb 2024 Form 4 Insider Report for AMGEN INC (AMGN)

Role: EVP, R&D, & Chief Sci. Officer
Signature: /s/ James E. Bradner
Issuer symbol: AMGN
Transactions as of: 09 Feb 2024
Net transactions value: $0
Form type: 4
Filing time: 12 Feb 2024, 19:50:46 UTC
Previous filing: 19 Dec 2023
Next filing: 09 May 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMGN	Common Stock	Award	$0	+8,587		$0.000000	8,587	09 Feb 2024	Direct	F1
transaction	AMGN	Common Stock	Award	$0	+13,806	+161%	$0.000000	22,393	09 Feb 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 2/9/2026, 2/9/2027 and 2/9/2028, respectively.
F2	These shares include the following RSUs granted under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan: 8,587 RSUs which will vest in installments of 2,833 on 2/9/2026, 2,834 on 2/9/2027, and 2,920 on 2/9/2028; and 13,806 RSUs which will vest in installments of 4,555 on 2/9/2026, 4,556 on 2/9/2027, and 4,695 on 2/9/2028. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

Content

The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 2/9/2026, 2/9/2027 and 2/9/2028, respectively.

These shares include the following RSUs granted under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan: 8,587 RSUs which will vest in installments of 2,833 on 2/9/2026, 2,834 on 2/9/2027, and 2,920 on 2/9/2028; and 13,806 RSUs which will vest in installments of 4,555 on 2/9/2026, 4,556 on 2/9/2027, and 4,695 on 2/9/2028. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.